Kaprex®
Tetrase™-Based Softgels by Oral Administration.
Dietary Supplement Dispensed by Healthcare Practitioner Recommendation.
(U.S. Patents 7,195,785 and 7,205,151.)

INDICATIONS AND USAGE
Kaprex is indicated for individuals with minor pain. Kaprex offers a safer approach and has been recommended for daily use with no serious adverse events reported.*

Established protein and genomic testing technologies and clinical evaluations demonstrate that Kaprex ingredients offer a high level of comparable efficacy with a leading competitor. These ingredients have been shown to be active in target tissues (e.g., joint) while exhibiting minimal activity in non-target tissues (e.g., gastrointestinal), making it an effective approach with a reduced risk of adverse events. It works by interfering with signals in the body that initiate the production of compounds that may negatively impact cartilage and other joint tissues.*

DESCRIPTION
Kaprex (in a dark, oblong softgel delivery form) is a dietary supplement formulated with a modified hops extract that has been demonstrated to modulate specific kinases associated with minor pain. Kinases function to chemically modify other proteins and help regulate eicosanoids (e.g., COX-2, PGE2), cytokines (e.g., TNF-α), reactive oxygen species (nitric oxide), and other mediators (e.g., NF-κB) that may negatively impact the body both locally and systemically. Research suggests kinase modulation is an attractive approach to target the origins of minor pain.*1-3

Kaprex effectively calms the body’s eicosanoid cascade by modulating enzyme formation in cells associated with minor pain. It does so without directly blocking constitutive (housekeeping) cyclooxygenase (COX) enzyme activity, a mechanism known to cause adverse effects with long-term use in some individuals. Instead, Kaprex indirectly modulates induced COX-2 proteins activated in response to stimuli.*

Kaprex and its primary active ingredients have been the subjects of proprietary cell proteomic research, safety evaluations, human ex vivo research, and human clinical research to help determine efficacy, bioavailability, and predicted safety.1 Clinical experience and tolerance tests demonstrate Kaprex to be well-tolerated.*

Each softgel supplies:
A proprietary blend of: 350 mg
• Tetrase™ (tetrahydro-iso-alpha acids complex, from hops, Humulus lupulus L.)
• Oleanolic Acid (from olive leaf extract, Olea europaea)
• Rosemary Leaf Extract (Rosmarinus officinalis)

Other Ingredients: Soybean oil, gelatin, glycerin, lecithin (soy), water, beeswax, and sodium copper chlorophyllin. Contains: soy.

Formulated to Exclude: Wheat, gluten, yeast, dairy products, nuts, tree nuts, fish, shellfish, or artificial colors, sweeteners, or preservatives.†

Figure 1. Chemical structures of substituted 1, 3-cyclopentadiones present in Tetrase.1

FORMULA MECHANISM OF ACTION
Selective kinase modulation
Unlike other approaches, Kaprex addresses the eicosanoid cascade upstream from COX-2 activity—specifically modulating kinases that influence signal transduction in the NF-κB pathway. NF-κB plays a critical role in the regulation of the eicosanoid cascade by activating transcription of genes, enzymes, and cytokines, including COX-2, TNF-α, and nitric oxide. Modulating kinases associated with the NF-κB signaling pathway has been demonstrated to provide tissue specificity for an effective but safer approach.*1-3

In vitro research with Tetrase, the key active ingredient in Kaprex (see “KEY INGREDIENT MECHANISM OF ACTION”), demonstrated the following:*1,4
• Modulation of kinases in NF-κB pathway—including BTK, SyK, BMX, PI3K (α,β,δ), PDK1, PKB (α,β,δ), GSK3 (α,β,δ), IRAK (1,4), TAB-1, TAK-1, and IKK (α,β)
• Inhibition of NF-κB activation (Figure 2) and related downstream events:
  ○ Luciferase activity
  ○ TNF-α activation
  ○ Nitric oxide production
  ○ COX-2 protein expression (Figure 3)
  ○ PGE2 production (Figure 4)

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
**SAFETY EVALUATIONS**

*Constitutive PGE<sub>2</sub> and COX-2 Biosynthesis*

Constitutive COX enzymes (1 & 2) and PGE<sub>2</sub> are vital to important housekeeping functions in the body—maintaining healthy blood pressure, renal flow, and gastrointestinal (GI) cellular maintenance and health. No significant effect on constitutive PGE<sub>2</sub> or COX-2 enzyme synthesis was observed through in vitro and ex vivo research with iso-alpha acids or a combination of iso-alpha acids, oleanolic acid, and rosemary extract. This suggests a higher degree of predicted safety.*7-9*

**Blood Pressure (BP)**

Clinical testing with a combination of iso-alpha acids, oleanolic acid, and rosemary extract demonstrated no significant effect on systolic or diastolic BP in 50 human subjects over 8 weeks. A second randomized, placebo-controlled trial of 32 subjects lasting 6 weeks yielded similar results.*9 Pooled data from these independent trials was examined to determine effects on hypertensive subjects; no significant difference was observed in systolic or diastolic BP.*7-9*

**Kidney & Liver Function**

No measurable effect in kidney function markers or electrolytes was observed in 2 short-term clinical studies (total n=82; see "Blood Pressure") with a combination of iso-alpha acids, oleanolic acid, and rosemary extract. These studies also showed that markers of liver function remained within reference ranges.*5-9*

**Cardiovascular Homeostasis: Urinary Prostanoid Excretion**

Urinary prostanoid excretion of PGI<sub>2</sub> (vasodilator) and TXA<sub>2</sub> (vasoconstrictor) are indicators of cardiovascular homeostasis, though neither is stable for detection. Instead, levels of PGI-M and TXB<sub>2</sub> were measured in two clinical studies (total n=8) with urine samples collected over 8 h in a comparison study that included administration of an iso-alpha acids/rosemary/oleanolic acid combination. Results were combined for analysis, which showed no significant increase in either biomarker with the nutritional supplement. Another approach, however, yielded a decrease in PGI-M (indicating a negative influence) and was in agreement with the suggestions of third-party research.*9-9*

**Gastrointestinal Homeostasis: Fecal Calprotectin**

Some approaches can significantly increase fecal calprotectin, which has been shown to be a reliable biomarker of adverse influence on the intestinal lining. Tetrase supplementation in human subjects (n=11) did not increase fecal calprotectin, a protein secreted by the GI immune system as a consequence of the cascade response.4 Two additional clinical studies with iso-alpha acids (total n=9) also displayed no significant effect on fecal calprotectin.7 A larger, 2-week, randomized, crossover study of 21 subjects that were administered an iso-alpha acids/rosemary extract/oleanolic acid combination demonstrated no significant changes in fecal calprotectin.*9,9-14 Separately, 8 subjects taking an iso-alpha acids/rosemary/oleanolic acid combination (along with other medications and/or nutritional supplements)
Figure 2. Cells were transiently transfected with NF-κB firefly luciferase construct for 2 days followed by 1 h pre-incubation with test compounds and 8 h LPS (1 μg/ml) stimulation. NF-κB luciferase activity was normalized with constitutively expressed Renilla luciferase. Data represent-mean +SEM-from 3 experiments.* p < 0.05 compared with LPS stimulation.¹

Figure 3. Cells were pre-incubated with 1-20 μg/ml Tetrase for 1 h and stimulated with LPS for 16 h for measurement of COX-2 with western blot.¹

Figure 4. Cells were pre-incubated with 1-20 μg/ml Tetrase for 1 h and stimulated with LPS for 4 h for measurement of PGE₂.¹

Figure 5. To evaluate the effect on constitutive (housekeeping) COX-2 activity, cells were LPS-stimulated for 20 h, followed by 1 h incubation with test compound. After PBS wash, compounds with LPS were added and incubated for 1 h and PGE₂ (produced by induced COX-2 activity) in the medium was determined.¹

Figure 6. In a mouse model, Tetrase was shown to promote maintenance of cartilage better than a leading conventional approach.*

Figure 7. After oral administration of 940 mg Tetrase by 4 healthy human volunteers, plasma was measured over an 8 h period. Peak levels were observed in 3 of the 4 subjects at 4 h.¹

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
were followed by a healthcare practitioner for 3 years at the Functional Medicine Research Center\(^1\); samples at random intervals also showed no significant changes in fecal calprotectin levels.*\(^9\)

**Platelet Function**

No direct effect on platelet function, coagulation, or complete blood counts was observed in 2 clinical studies (total n=82, see “Blood Pressure”) with a combination of iso-alpha acids, oleanolic acid, and rosemary extract.\(^9\)

**CAUTIONS**

**General**

Patients with a hypersensitivity to ingredients in Kaprex should avoid use.

**Pregnancy and Nursing**

Due to a lack of testing in these individuals, Kaprex is not recommended for pregnant or nursing women.

**Children**

This product is not recommended for use in children.

**ADVERSE REACTIONS**

No serious adverse events reported as of April 2009.

**POTENTIAL DRUG/NUTRIENT INTERACTIONS**

**Anti-Coagulants (Warfarin, Heparin)**

Theoretically, concomitant use with anticoagulants can cause additive therapeutic and potential adverse effects.

**STORAGE**

Keep tightly closed in a cool, dry place.

**DOSAGE AND ADMINISTRATION:** One softgel with food

**HOW SUPPLIED:** 20 and 60 Softgel Bottles

**REFERENCES**

28. This product is manufactured in a facility that produces products containing soy, dairy, nuts, tree nuts, fish, and shellfish.
29. At MetaProteomics, Inc. and the Functional Medicine Research Center\(^\dagger\), the research arms of Metagenics, Inc.

Kaprex is part of a select group of novel formulations that set a new standard of clinical certainty in natural products by demonstrating efficacy, bioavailability, and a high level of predicted safety.*

\* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.